FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner FDA Removes 12 Peptides from 503A Category 2 Newtropin FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg #